Sou Hu Cai Jing·2025-05-07 10:30Core Viewpoint - WuXi AppTec's stock closed at 58.25 yuan, down 3.46%, with a rolling PE ratio of 15.05 times and a total market capitalization of 168.23 billion yuan [1] Company Summary - WuXi AppTec provides integrated, end-to-end drug development and manufacturing services for the global pharmaceutical and life sciences industries [1] - The company's main business segments include chemical services, testing services, and biological services [1] - For Q1 2025, WuXi AppTec reported revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, a year-on-year increase of 89.06%, with a gross profit margin of 42.26% [1] Industry Summary - The average PE ratio for the medical services industry is 38.69 times, with a median of 38.36 times, placing WuXi AppTec at 17th in the industry ranking [1][2] - As of Q1 2025, 385 institutions held shares in WuXi AppTec, including 378 funds, with a total shareholding of 1,109.79 million shares valued at 74.711 billion yuan [1]